@asininitybeyond Thats what harnessing the most potent topo1 drug inexistance 'Exatecan' looks like in preclinical. We already know there are more indications that are suitable for AVA6103 behind the first 4 selected so the scope here is huge. The fact they have selected 4 very difficult to

AVA6103 looks dynamite. All models chemo resistant. 4 major indications showing near flawless, durable responses. Plus the broad application of FAP targeting. A company-maker. Going in man within weeks. Earns #AVCT the right to be talked about alongside big $$$.2/2 #JPM26

$RVMD disclosed their 2nd Gen RAS(ON) inhibitor at #JPM26. Pre-clinical data looks really impressive + likely besting its own 1st Gen lead asset(s). Commentators suggesting the rumoured $32bn offer from $MRK needs upped! But how does it compare to #AVCT’s AVA6103 pre-clin? 1/2

AbbVie acquires ex-China rights to RemeGen’s BsAb RC148 for $650m upfront + ~$5bn total potential - P2 drug with potential wide utility + promising early anti-tumour activity. $ABBV notes the drugs impact on the TME + immune response. Lucrative LD opportunities out there. #AVCT

#AVCT at JP Morgan Healthcare Conference next week. They’ve attended before but splashing it on social media is new behaviour. Most are pining for commercial progress + some big pharma cash, so lets see what comes. Regardless, participation is positive for SHs. Good luck all!

Meanwhile, Gilead signs $300m deal to access OncoNano’s P1 stage ‘On-Board’ drug delivery platform, collaborating on a drug of Gilead’s choosing $300m to access On-Board, not licence an asset Hence why #AVCT so focused on the platform Some of the below might sound familiar ⬇️

Amgen buys Oxford Uni spin-out for up to $840m. 3 assets - all pre-clinical. Amgen enticed early by the promise shown in the lab, as well as differentiation. Yet #AVCT’s “PDC IP is too new”, “it’s too different”, “it’s too early for big money”etc. Nonsense. We are ready.

Great chart demonstrating why BP needs new blockbusters to shore up cliff edges Not a company level problem, rather across the sector Pharma Biz Development execs likely rubbing their eyes when they see a drug production factory like #AVCT + its platform https://t.co/ksl9BuuCDw

Safety + tolerability improvements are key. There is more to it than just efficacy With Abs safety concessions are made. #AVCT is removing that compromise $MRK has a huge oncology gap to fill as Keytruda approaches LOE. Cue preCISON Novartis is in play. Who else? 2/2

$MRK + $DSNKY running into challenges again with an ADC from their $5.5bn DXd platform tie up B7-H3-targeting ifinatamab deruxtecan lung trial on hold due to lung toxicity death. ILD is a big challenge for ADC. Drug development is hard. #AVCT 1/2

“[the data] continue to demonstrate the power of our pre|CISION® platform, with optimal payload release observed even at the lowest levels of FAP expression. This supports a broad market opportunity for all pre|CISION® medicines..." All about the platform ➡️ What follows? #AVCT

Kymera has a single clinical drug plus a pre-clin pipeline. Lead asset just entered P2 for dermatitis + asthma to follow $6.5bn MCAP, just raised $500m… Kymera arguably a bit overvalued but #AVCT clearly the opposite IMO And shows what can happen with good data + US presence!

Auction was initiated = 4 bidders + offer price almost doubled in weeks All aided by recent FDA Fast Track & Breakthrough designations for lead asset Cidara uses small molecule/peptide conjugation platform tech #AVCT looking perfectly positioned IMO 2/2 https://t.co/DtMpgMjwUy

To conveniently demonstrate that interest 👆, details of the Cidara-$MRK deal are out in the SEC filing. Deal background is absolutely worth a read! $9.2bn final price agreed last month but business development discussions ongoing since Nov 24.1/2 #AVCT https://t.co/jSDdCYe6MC

However, I am confident #AVCT gets spoken about alongside these sorts of numbers soon enough In the meantime, lots of comfort to be taken from what Avacta has in its IP, demand that will drive in terms of buyer interest + the buoyancy of the biotech sector after a tough run. 2/2

Chatter suggests still lots of BP interest in Biotech JPM HC next month - prime deal-making venue “Business Development” takes different forms + often happens over time. So, licence deals, while not the end-game, may well be the foundations for #AVCT’s eventual acquisition. 1/2

For those who say no one cares about PFS, more time doesnt matter + it all about a cure $LLY’s Onco President @ c5min: “We’re not done until we've either cured this disease or *turned it into a chronic illness that people can live a long time with* https://t.co/SMMPcOO8G4 #AVCT

Eliminate CAFs ➡️ Compromise the stroma ➡️ elicit a durable immune response #AVCT way ahead of the game on this, with a platform that is all-in on FAP Expect more biotechs to raise their heads in respect of CAF (+ FAP) targeting given the appetite trend https://t.co/8iaJo04NCY

Across the platform + the range of assets derived from it, the benefit is greatly amplified Further throw in operational cost savings of materially reducing dev timeframes + it’s beyond compelling for pharma #AVCT really has it all + will be sold for a huge sum. All IMO! 3/3

This paper shows the benefit of route to market acceleration: $5-6m per month NOV per $1bn sales. To model this, using PL’s 6103 projection of $1.5bn peak sales (with low case 24 month reduction in time to market + lower $5m p/m benefit) asset NPV improves by up to 50%.2/3 #AVCT